Ebola virus is a highly lethal human pathogen and is rapidly driving many wild primate populations toward extinction. Several lines of evidence suggest that innate, nonspecific host factors are potentially critical for survival after Ebola virus infection. Here, we show that nonreplicating Ebola virus-like particles (VLPs), containing the glycoprotein (GP) and matrix protein virus protein (VP)40, administered 1–3 d before Ebola virus infection rapidly induced protective immunity. VLP injection enhanced the numbers of natural killer (NK) cells in lymphoid tissues. In contrast to live Ebola virus, VLP treatment of NK cells enhanced cytokine secretion and cytolytic activity against NK-sensitive targets. Unlike wild-type mice, treatment of NK-deficient or -depleted mice with VLPs had no protective effect against Ebola virus infection and NK cells treated with VLPs protected against Ebola virus infection when adoptively transferred to naive mice. The mechanism of NK cell–mediated protection clearly depended on perforin, but not interferon-γ secretion. Particles containing only VP40 were sufficient to induce NK cell responses and provide protection from infection in the absence of the viral GP. These findings revealed a decisive role for NK cells during lethal Ebola virus infection. This work should open new doors for better understanding of Ebola virus pathogenesis and direct the development of immunotherapeutics, which target the innate immune system, for treatment of Ebola virus infection.
Skip Nav Destination
Article navigation
19 July 2004
Article|
July 12 2004
Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection
Kelly L. Warfield,
Kelly L. Warfield
1United States Army Medical Research Institute of Infectious Diseases
Search for other works by this author on:
Jeremy G. Perkins,
Jeremy G. Perkins
4Department of Hematology and Oncology, Walter Reed Army Medical Center, Washington DC 20307
Search for other works by this author on:
Dana L. Swenson,
Dana L. Swenson
1United States Army Medical Research Institute of Infectious Diseases
Search for other works by this author on:
Emily M. Deal,
Emily M. Deal
1United States Army Medical Research Institute of Infectious Diseases
Search for other works by this author on:
Catharine M. Bosio,
Catharine M. Bosio
2Clinical Research Management,
Search for other works by this author on:
M. Javad Aman,
M. Javad Aman
2Clinical Research Management,
Search for other works by this author on:
Wayne M. Yokoyama,
Wayne M. Yokoyama
5Howard Hughes Medical Institute, Rhuematology Division, Washington University School of Medicine, St. Louis, MO 63110
Search for other works by this author on:
Howard A. Young,
Howard A. Young
3Laboratory of Experimental Immunology, National Cancer Institute, Frederick, Maryland 21702
Search for other works by this author on:
Sina Bavari
Sina Bavari
1United States Army Medical Research Institute of Infectious Diseases
Search for other works by this author on:
Kelly L. Warfield
1United States Army Medical Research Institute of Infectious Diseases
Jeremy G. Perkins
4Department of Hematology and Oncology, Walter Reed Army Medical Center, Washington DC 20307
Dana L. Swenson
1United States Army Medical Research Institute of Infectious Diseases
Emily M. Deal
1United States Army Medical Research Institute of Infectious Diseases
Catharine M. Bosio
2Clinical Research Management,
M. Javad Aman
2Clinical Research Management,
Wayne M. Yokoyama
5Howard Hughes Medical Institute, Rhuematology Division, Washington University School of Medicine, St. Louis, MO 63110
Howard A. Young
3Laboratory of Experimental Immunology, National Cancer Institute, Frederick, Maryland 21702
Sina Bavari
1United States Army Medical Research Institute of Infectious Diseases
Address correspondence to Sina Bavari, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Frederick, MD 21702. Phone: (301) 619-4246; Fax: (301) 619-2348; email: [email protected]
Abbreviations used in this paper: GP, glycoprotein; MCMV, murine cytomegalovirus; MIP, macrophage inflammatory protein; moi, multiplicity of infection; VLP, virus-like particle; VP, viral protein.
Received:
December 10 2003
Accepted:
June 09 2004
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2004
J Exp Med (2004) 200 (2): 169–179.
Article history
Received:
December 10 2003
Accepted:
June 09 2004
Citation
Kelly L. Warfield, Jeremy G. Perkins, Dana L. Swenson, Emily M. Deal, Catharine M. Bosio, M. Javad Aman, Wayne M. Yokoyama, Howard A. Young, Sina Bavari; Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection . J Exp Med 19 July 2004; 200 (2): 169–179. doi: https://doi.org/10.1084/jem.20032141
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement